Credit: Getty Images. The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone. Pfizer announced findings from a phase3b/4 trial evaluating the efficacy and ...

MADRID -- Rheumatoid arthritis patients taking tofacitinib (Xeljanz) plus methotrexate who achieved low disease activity (LDA) may be able to withdraw from the latter agent without significant ...

Elevated levels of the inflammatory biomarkers myeloid related protein 8/14 predict an increased risk of relapse following withdrawal of methotrexate therapy in children with juvenile idiopathic ...

For patients with juvenile idiopathic arthritis in remission, withdrawal of treatment with the drug methotrexate over 12 months vs. 6 months did not reduce the rate of relapse, according to a new ...

July 22, 2009 — Intensive treatment with methotrexate may be helpful in early rheumatoid arthritis despite greater adverse events vs conventional treatment, according to the results of a study ...

Please provide your email address to receive an email when new articles are posted on . Patients with rheumatoid arthritis treated with tofacitinib experienced efficacy and safety outcomes comparable ...

Pfizer Inc announced positive results from ORAL Shift, a phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA). Patients who achieved low disease activity ...

Copenhagen, Denmark, Thursday 11 June 2009: Elevated levels of the inflammatory biomarkers Myeloid Related Protein (MRP*) 8/14 predict an increased risk of relapse following withdrawal of methotrexate ...